Key Takeaways:
Veracyte reported Q2 EPS of 54 cents, beating the 24-cent consensus, on revenue of $150.3 million that topped estimates.
The South San Francisco-based genomic diagnostics company, which trades on the Nasdaq, said the results reflected continued demand for its Afirma thyroid test and Decipher prostate cancer assay, according to its earnings release.
Revenue of $150.3 million came in about $2.9 million, or roughly 2 percent, above the $147.4 million consensus. Earnings per share of 54 cents compared with the 24-cent average analyst estimate, a beat of about 30 cents.
The beat extends Veracyte's run of topping Wall Street expectations as it expands its installed base of genomic tests. The company did not disclose updated full-year guidance in the release; investors will watch the earnings call for margin and volume commentary.
Veracyte's Afirma test, used to guide thyroid nodule management, and Decipher, which informs prostate cancer treatment decisions, anchor a portfolio that also includes the Envisia genomic classifier for interstitial lung disease. The company competes with Exact Sciences and Myriad Genetics in the molecular diagnostics space, where test volume and reimbursement rates determine profitability.
The company did not disclose year-over-year revenue growth or a stock price reaction in the release. Analysts will look for volume trends across its test franchises when management speaks on the earnings call, with Afirma and Decipher together driving the bulk of revenue.
The beat comes as the molecular diagnostics sector faces reimbursement pressure from payers, making volume growth and test pricing key swing factors for Veracyte's margin trajectory. A 123 percent EPS beat against consensus suggests operating leverage is building as the company scales its test volumes, though the sustainability of that pace depends on how quickly it can convert new accounts into recurring testing.
The 123 percent EPS beat signals operating leverage is building as Veracyte scales its test volumes. Investors will watch the earnings call for updated guidance and commentary on reimbursement trends.
This article is for informational purposes only and does not constitute investment advice.
